177Lu-DOTA0-Tyr3-Octreotate

DRUG4 trials

Conditions

Carcinoid Tumor of the Small BowelNeuroendocrine TumorsNeuroendocrine TumourPancreatic Neuroendocrine CarcinomaSmall Cell Lung CancerSmall Cell Lung Cancer Extensive Stage

Phase 1

Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

CompletedNCT03325816

Georgetown UniversitySmall Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage

Start: 2017-11-20End: 2020-08-11Updated: 2021-03-16

Phase 2

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

CompletedNCT02230176

Gustave Roussy, Cancer Campus, Grand ParisPancreatic Neuroendocrine Carcinoma

Start: 2015-02-28End: 2024-04-30Updated: 2025-04-20

Phase 3

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

CompletedNCT01578239

Advanced Accelerator ApplicationsCarcinoid Tumor of the Small Bowel, Neuroendocrine Tumour

Start: 2012-09-06End: 2021-01-18Updated: 2022-04-04

Unknown Phase

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

NCT02705313

Advanced Accelerator ApplicationsNeuroendocrine Tumors

Updated: 2018-04-09

Nuclear Medicine Communications2023-10-304 citations

Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.

2022-04-136 citations

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

2021-11-15378 citations

Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.

Journal of Clinical Oncology2021-05-2069 citations

Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung

Journal for ImmunoTherapy of Cancer2020-07-0180 citations

Safety of 177Lu-DOTATATE in patients with advanced neuroendocrine tumors: Data from a U.S. expanded access program.

Journal of Clinical Oncology2020-05-20

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

European Journal of Nuclear Medicine and Molecular Imaging2020-03-02112 citations

Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study

Annals of Oncology2018-10-016 citations

First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.

Journal of Clinical Oncology2018-05-2028 citations

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for patients with extensive-stage small cell lung cancer.

Journal of Clinical Oncology2018-05-203 citations

Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.

Journal of Clinical Oncology2017-02-013 citations

Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors

New England Journal of Medicine2017-01-113002 citations

NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE.

Journal of Clinical Oncology2016-05-206 citations

NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate.

Journal of Clinical Oncology2016-02-0162 citations